Dr. Robert J. Behrens

About Robert J. Behrens

Education:

• Graduated with a BS in Chemistry, with distinction, from Iowa State University, 1992.
• Earned an MD from the University of Iowa College of Medicine, 1997.

Experience:

• Completed Residency in Internal Medicine at Johns Hopkins University / Sinai Hospital, 2000.
• Fellowship in immuno-therapy of cancer at the National Cancer Institute, 2003.
• Joined Mission Cancer + Blood in 2003, with board certifications in Medical Oncology, Hematology, and Internal Medicine.
• Actively involved in national cancer vaccine trials and serves at multiple medical centers.

Area of expertise

Affiliated Hospitals

Iowa Methodist Medical Center

Medical Oncology And Hematology Associates-Des Moines

Clinical Trials Robert J. Behrens is currently running

Chemotherapy + Radiotherapy

for Esophageal and Gastric Cancer

This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.

Recruiting2 awards Phase 320 criteria

Pembrolizumab + TKI

for Chronic Myeloid Leukemia

This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.

Recruiting1 award Phase 2

More about Robert J. Behrens

Other Doctors you might be interested in

Frequently asked questions